MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12020-025-04433-2

Медицинская библиотека · Endocrine · 2025

Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.

Zhang Yuanpin, Li Yujia, Cui Qiaoli, Zheng Hangping, Sun Wanwan, Chen Lili, Zhu Xiaoming, Li Yiming, Ye Hongying, Zhang Shuo, Liu Xiaoxia, Ji Lijin

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To evaluate the prevalence of hypogonadotropic hypogonadism (HH) in male prolactinoma patients with dopamine agonist (DA) therapy and explore the predictive factors of hypogonadism recovery.

DESIGN

Retrospective study from a single center.

METHODS

A cohort of male prolactinoma patients who were under medical therapy for at least one year with regular follow-up from the special outpatient clinic in Huashan Hospital was reviewed. Demographic details, clinical features, hormonal profile, medication, imaging characteristics were recorded at diagnosis and during the timeline follow-up. FINDINGS: A total of 73 male prolactinoma patients with median age of 35 (31–51) years old, and BMI of 24.9 ± 2.7 kg/m2 were included. The prevalence of HH at diagnosis was 87.7%. After 2.5 (1.5–3.4) years of DA therapy, 71.4% of HH patients recovered after prolactin normalization. Compared to those with persistent HH, patients with HH recovery had lower baseline BMI (24.2 ± 2.4 vs. 26.4 ± 2.7 kg/m2, p = 0.002), and higher baseline testosterone (4.28 [3.32–6.03] vs. 2.34 [1.36–4.35] nmol/L, p = 0.007). The multivariate logistic regression analysis demonstrated that patients with higher testosterone level (OR 1.679 [1.134–2.487]) or lower BMI (OR 0.761 [0.592–0.977]) at diagnosis had significantly greater possibility of HH recovery, after adjusting for prolactin, adenoma maximal diameter and vision changes.

CONCLUSIONS

HH is common in male prolactinoma patients and 71.4% of them recovered from HH after prolactin normalization treated by DA. Baseline testosterone and BMI were identified as independent predictors of HH recovery in men with prolactinoma.

Для цитирования: Zhang Yuanpin, Li Yujia, Cui Qiaoli, Zheng Hangping, Sun Wanwan, Chen Lili, Zhu Xiaoming, Li Yiming, Ye Hongying, Zhang Shuo, Liu Xiaoxia, Ji Lijin. Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.. Endocrine. 2025. DOI: 10.1007/s12020-025-04433-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.